- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Biovest Secures Agreement for Lymphoma Vaccine BiovaxID
Biovest, makers of BiovaxID, an immunotherapy and a therapeutic vaccine to treat follicular non-Hodgkin's lymphoma, has reached an agreement with Stellar Biotechnologies, Inc. that will allow Biovest to move forward in developing BiovaxID.
BiovaxID is is an immunotherapy that brings together an "autologous heterohybridoma-derived tumor idiotype protein" (in other words, a protein derived from and exclusive to the patient's tumor, engineered to elicit a response from the immune system) with a carrier molecule.
Stellar manufactures Keyhole Limpet Hemocyanin (KLH), which is an immune-stimulating protein that is also used as a carrier molecule.
BiovaxID has successfully completed Phase 2 and Phase 3 clinical trial development and is currently the subject of a Marketing Authorization Application (MAA) under review by the European Medicines Agency (EMA).
"Stellar's key growth initiative is to leverage our Stellar KLH(TM) technology into multiple clinical pathways and the BiovaxID(R) program is a good example of the value of our core business for this purpose," said Frank Oakes, President and CEO of Stellar Biotechnologies, Inc. "There are many new KLH-based immunotherapies advancing in clinical trials and we are positioning Stellar to be the leading company capable of delivering the scalable, sustainable supplies of KLH that will be needed by these pharmaceutical pipelines."
"We are pleased to collaborate with Stellar Biotechnologies to continue the clinical progress of our active immunotherapy (BiovaxID) and are proud to work with Stellar in anticipation of our future commercial success," said Carlos Santos, Chief Executive Officer of Biovest. "BiovaxID immunotherapy has demonstrated ability in long-running clinical trials to elicit potent anti-tumor immune responses and extend remission duration in patients suffering from follicular non-Hodgkin's lymphoma. If approved, we anticipate that this product will offer an innovative adjuvant/consolidation vaccine strategy for patients with this disease."